IL165478A - Humanized anti-myelin associated glycoprotein (mag) antibody and pharmaceutical composition comprising such antibody - Google Patents

Humanized anti-myelin associated glycoprotein (mag) antibody and pharmaceutical composition comprising such antibody

Info

Publication number: IL165478A
Authority: IL; Israel
Prior art keywords: antibody; mag; pharmaceutical composition; humanized anti; associated glycoprotein
Prior art date: 2002-08-06

Application number

IL165478A

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-08-06

Filing date

2004-11-30

Publication date

2010-12-30

2002-08-06 Priority claimed from GB0218229A external-priority patent/GB0218229D0/en

2002-08-06 Priority claimed from GB0218230A external-priority patent/GB0218230D0/en

2002-08-06 Priority claimed from GB0218234A external-priority patent/GB0218234D0/en

2002-08-06 Priority claimed from GB0218232A external-priority patent/GB0218232D0/en

2004-11-30 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2010-12-30 Publication of IL165478A publication Critical patent/IL165478A/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Public Health (AREA)
Neurology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Neurosurgery (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Psychology (AREA)
Microbiology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Hospice & Palliative Care (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Psychiatry (AREA)
Mycology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

IL165478A 2002-08-06 2004-11-30 Humanized anti-myelin associated glycoprotein (mag) antibody and pharmaceutical composition comprising such antibody IL165478A (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
GB0218229A GB0218229D0 (en)	2002-08-06	2002-08-06	Antibodies
GB0218230A GB0218230D0 (en)	2002-08-06	2002-08-06	Antibodies
GB0218234A GB0218234D0 (en)	2002-08-06	2002-08-06	Antibodies
GB0218232A GB0218232D0 (en)	2002-08-06	2002-08-06	Antibodies
PCT/EP2003/008749 WO2004014953A2 (en)	2002-08-06	2003-08-05	Anti-myelin associated glycoprotein (mag) antibodies

Publications (1)

Publication Number	Publication Date
IL165478A true IL165478A (en)	2010-12-30

Family

ID=31721633

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL165478A IL165478A (en)	2002-08-06	2004-11-30	Humanized anti-myelin associated glycoprotein (mag) antibody and pharmaceutical composition comprising such antibody

Country Status (23)

Country	Link
US (2)	US7612183B2 (en)
EP (1)	EP1526868B1 (en)
JP (1)	JP4528121B2 (en)
KR (1)	KR101078459B1 (en)
CN (1)	CN100542607C (en)
AR (1)	AR040778A1 (en)
AU (1)	AU2003255390B2 (en)
BR (1)	BR0312456A (en)
CA (1)	CA2494008C (en)
CY (1)	CY1114919T1 (en)
DK (1)	DK1526868T3 (en)
ES (1)	ES2440652T3 (en)
IL (1)	IL165478A (en)
IS (1)	IS7576A (en)
MX (1)	MXPA05001468A (en)
MY (1)	MY148409A (en)
NO (1)	NO333876B1 (en)
NZ (1)	NZ537123A (en)
PL (1)	PL211014B1 (en)
PT (1)	PT1526868E (en)
SI (1)	SI1526868T1 (en)
TW (1)	TWI323265B (en)
WO (1)	WO2004014953A2 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1355666B1 (en)	2000-12-22	2012-06-13	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Use of repulsive guidance molecule (RGM) and its modulators
GB0103174D0 (en) *	2001-02-08	2001-03-28	Smithkline Beecham Plc	Novel method of treatment
TWI323265B (en) *	2002-08-06	2010-04-11	Glaxo Group Ltd	Antibodies
GB0306309D0 (en) *	2003-03-19	2003-04-23	Glaxo Group Ltd	Method of treatment
DK2161336T4 (en) *	2005-05-09	2017-04-24	Ono Pharmaceutical Co	Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
WO2007039256A2 (en)	2005-09-30	2007-04-12	Abbott Gmbh & Co. Kg	Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use
KR20170002684A (en)	2005-11-04	2017-01-06	제넨테크, 인크.	Use of complement pathway inhibitors to treat ocular diseases
KR100981202B1 (en) *	2006-05-31	2010-09-10	한화케미칼 주식회사	WCA-1 specific monoclonal antibody
TWI472535B (en)	2006-11-02	2015-02-11	Genentech Inc	Humanized anti-factor d antibodies and uses thereof
EP2212431A4 (en) *	2007-10-16	2011-05-11	Nuvelo Inc	ANTI-IREM-1 ANTIBODIES
US8962803B2 (en)	2008-02-29	2015-02-24	AbbVie Deutschland GmbH & Co. KG	Antibodies against the RGM A protein and uses thereof
CR20170001A (en) *	2008-04-28	2017-08-10	Genentech Inc	ANTI FACTOR D HUMANIZED ANTIBODIES
PE20091965A1 (en)	2008-05-06	2010-01-09	Glaxo Group Ltd	ENCAPSULATION OF BIOLOGICALLY ACTIVE AGENTS
AR074777A1 (en)	2008-12-19	2011-02-09	Glaxo Group Ltd	PROTEINS OF UNION TO ANTIGEN
CA2749966A1 (en) *	2009-01-29	2010-08-05	Abbott Laboratories	Il-1 binding proteins
US20110165063A1 (en) *	2009-01-29	2011-07-07	Abbott Laboratories	Il-1 binding proteins
CA2780069C (en)	2009-12-08	2018-07-17	Abbott Gmbh & Co. Kg	Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
WO2011085289A1 (en) *	2010-01-11	2011-07-14	Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University	Production of a monoclonal antibody therapeutic against west nile virus in plants
UY33421A (en)	2010-06-03	2011-12-30	Glaxo Wellcome House	HUMANIZED ANTIGEN UNION PROTEINS
AU2011267869A1 (en)	2010-06-14	2013-01-10	Vaccinex, Inc.	Anti-VEGF antibodies and uses thereof
US8974782B2 (en) *	2011-02-07	2015-03-10	Glaxo Group Limited	Treatment of stroke comprising anti-MAG antibodies
MX391536B (en)	2012-01-27	2025-03-21	Abbvie Deutschland	COMPOSITION AND METHOD FOR THE DIAGNOSIS AND TREATMENT OF DISEASES ASSOCIATED WITH NEURITE DEGENERATION.
US9308196B2 (en) *	2012-05-18	2016-04-12	Gruenenthal Gmbh	Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
CN107318267B (en)	2013-08-12	2021-08-17	豪夫迈·罗氏有限公司	Compositions and methods for treating complement-related disorders
BR112016012229A2 (en)	2013-12-20	2017-09-26	Hoffmann La Roche	polypeptide production methods
RU2760005C2 (en)	2014-03-13	2021-11-22	Университет Базель	CARBOHYDRATE LIGANDS THAT BIND TO IgM ANTIBODIES AGAINST MYELIN-ASSOCIATED GLYCOPROTEIN
PE20161440A1 (en)	2014-05-01	2017-01-26	Genentech Inc	VARIANTS OF THE ANTI-FACTOR D ANTIBODY AND THEIR USES
AU2016282334B2 (en)	2015-06-24	2022-07-21	F. Hoffmann-La Roche Ag	Anti-transferrin receptor antibodies with tailored affinity
AU2016323377B2 (en)	2015-09-16	2021-04-15	Universität Basel	Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids
CA2997963A1 (en) *	2015-09-29	2017-04-06	Celgene Corporation	Pd-1 binding proteins and methods of use thereof
PE20231655A1 (en)	2015-10-02	2023-10-17	Hoffmann La Roche	BISPECIFIC ANTIBODIES AGAINST HUMAN CD20 AND THE HUMAN TRANSFERRIN RECEPTOR AND METHODS OF USE
AR106189A1 (en)	2015-10-02	2017-12-20	Hoffmann La Roche	BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE
TW201730211A (en)	2015-10-30	2017-09-01	建南德克公司	Anti-Factor D antibodies and conjugates
EP3368090A1 (en)	2015-10-30	2018-09-05	H. Hoffnabb-La Roche Ag	Anti-factor d antibody variant conjugates and uses thereof
JP2019534859A (en)	2016-09-19	2019-12-05	セルジーンコーポレイション	Method for treating vitiligo using PD-1 binding protein
MX2019002867A (en)	2016-09-19	2019-11-12	Celgene Corp	Methods of treating immune disorders using pd-1 binding proteins.
CN109481673A (en) *	2017-09-12	2019-03-19	中国科学院苏州纳米技术与纳米仿生研究所	The composition of promotion cerebral injury neural restoration and its application and evaluation method

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS57106673A (en)	1980-12-24	1982-07-02	Chugai Pharmaceut Co Ltd	Dibenzo(b,f)(1,4)oxazepin derivative
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
DK84787D0 (en)	1987-02-19	1987-02-19	Axel Olsen	LISTING SYSTEM FOR ELECTRIC POWER SUPPLY AND / OR POWER CONTROLLERS
EP0307434B2 (en)	1987-03-18	1998-07-29	Scotgen Biopharmaceuticals, Inc.	Altered antibodies
US4873316A (en)	1987-06-23	1989-10-10	Biogen, Inc.	Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5250414A (en)	1988-11-04	1993-10-05	Erziehungsdirektion Of The Canton Zurich	Diagnostic methods using neurite growth regulatory factors
US5154927A (en) *	1989-01-19	1992-10-13	Wm. Wrigley Jr. Company	Gum composition containing dispersed porous beads containing active chewing gum ingredients and method
US5182107A (en)	1989-09-07	1993-01-26	Alkermes, Inc.	Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5527527A (en)	1989-09-07	1996-06-18	Alkermes, Inc.	Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5154924A (en)	1989-09-07	1992-10-13	Alkermes, Inc.	Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
FI93513C (en)	1993-11-04	1995-04-25	Matti Kangasvuori	Chain and method of making a chain
CA2182013C (en) *	1994-01-25	2007-07-17	Mary M. Bendig	Humanized antibodies against leukocyte adhesion molecule vla-4
GB9403250D0 (en) *	1994-02-21	1994-04-13	Univ Mcgill	Therapeutic use of myelin-associated glycoprotein (mag)
GB9424449D0 (en)	1994-12-02	1995-01-18	Wellcome Found	Antibodies
KR19990007893A (en)	1995-04-19	1999-01-25	론 코헨	Central nervous system (CNS) axon growth modulator, compositions, cells and methods for implementing and using the same
US5792743A (en)	1995-04-19	1998-08-11	Acorda Therapeutics	Method for promoting neural growth comprising administering a soluble neural cell adhesion molecule
US6576607B1 (en)	1995-04-19	2003-06-10	Acorda Therapeutics	Methods using CNS neurite outgrowth modulators
ATE275415T1 (en)	1995-06-27	2004-09-15	Res Foundation Of Cuny Hunter	COMPOSITION CONTAINING A MYELIN-ASSOCIATED GLYCOPROTEIN (MAG) INHIBITOR WHICH CONTAINS AN ALTERED OR MUTATED FORM OF MAG
JP3925663B2 (en) *	1995-06-30	2007-06-06	持田製薬株式会社	Anti-Fas ligand antibody and measurement method using the antibody
WO1997007810A1 (en)	1995-08-25	1997-03-06	The John Hopkins University School Of Medicine	Compounds for stimulating nerve growth
US5834597A (en) *	1996-05-20	1998-11-10	Protein Design Labs, Inc.	Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
EP0941345A2 (en) *	1996-09-20	1999-09-15	The General Hospital Corporation	Chimeric, humanized and single chain antibodies to alpha-2-antiplasmin
DE69818106T2 (en)	1997-10-28	2004-06-17	The University Of British Columbia, Vancouver	IMMUNOLOGICAL COMPOSITIONS AND METHOD FOR TRANSIENTALLY MODIFYING THE CENTRAL VENEER SYSTEM MYELINE OF MAMMALS AND PROMOTING NERVOUS REGENERATION
CN1294517A (en)	1997-11-14	2001-05-09	欧洲细胞技术有限公司	Immunoglobulin molecules having synthetic variable region and modified specificity
WO1999053945A1 (en) *	1998-04-16	1999-10-28	Samuel David	Neuron growth inhibitory molecules or derivatives thereof used to immunize mammals thereby promoting axon regeneration
GB9809839D0 (en)	1998-05-09	1998-07-08	Glaxo Group Ltd	Antibody
WO2000005364A1 (en)	1998-07-22	2000-02-03	Smithkline Beecham Plc	Protein similar to neuroendrocrine-specific protein, and encoding cdna
CN1326466A (en) *	1998-09-14	2001-12-12	拉斯·奥斯特加德·佩德森	A method of producing functional immunoglobulin superfamily proteins
ES2529196T3 (en)	1998-11-06	2015-02-17	University Of Zurich	Nucleotide and protein sequences of Nogo genes and methods based on these
AU775525B2 (en)	1999-01-22	2004-08-05	Auckland Technology Enabling Corporation Limited	Vaccine-mediated treatment of neurological disorders
GB9908533D0 (en)	1999-04-14	1999-06-09	Novartis Ag	Organic compounds
US8101553B1 (en) *	2000-02-22	2012-01-24	Medical & Biological Laboratories Co., Ltd.	Antibody library
GB0103174D0 (en) *	2001-02-08	2001-03-28	Smithkline Beecham Plc	Novel method of treatment
US20040002790A1 (en)	2002-06-28	2004-01-01	Paul Senn	Sensitive devices and sensitive applications
TWI323265B (en)	2002-08-06	2010-04-11	Glaxo Group Ltd	Antibodies
GB0306309D0 (en)	2003-03-19	2003-04-23	Glaxo Group Ltd	Method of treatment

2003
- 2003-08-04 TW TW092121286A patent/TWI323265B/en not_active IP Right Cessation
- 2003-08-04 AR AR20030102790A patent/AR040778A1/en not_active Application Discontinuation
- 2003-08-05 PL PL375405A patent/PL211014B1/en unknown
- 2003-08-05 KR KR1020057002132A patent/KR101078459B1/en not_active Expired - Fee Related
- 2003-08-05 NZ NZ537123A patent/NZ537123A/en not_active IP Right Cessation
- 2003-08-05 BR BR0312456-8A patent/BR0312456A/en not_active IP Right Cessation
- 2003-08-05 MY MYPI20032945A patent/MY148409A/en unknown
- 2003-08-05 JP JP2004526901A patent/JP4528121B2/en not_active Expired - Fee Related
- 2003-08-05 SI SI200332328T patent/SI1526868T1/en unknown
- 2003-08-05 EP EP03784195.4A patent/EP1526868B1/en not_active Expired - Lifetime
- 2003-08-05 PT PT37841954T patent/PT1526868E/en unknown
- 2003-08-05 MX MXPA05001468A patent/MXPA05001468A/en active IP Right Grant
- 2003-08-05 CA CA2494008A patent/CA2494008C/en not_active Expired - Fee Related
- 2003-08-05 DK DK03784195.4T patent/DK1526868T3/en active
- 2003-08-05 CN CNB03818477XA patent/CN100542607C/en not_active Expired - Fee Related
- 2003-08-05 US US10/523,295 patent/US7612183B2/en not_active Expired - Fee Related
- 2003-08-05 ES ES03784195.4T patent/ES2440652T3/en not_active Expired - Lifetime
- 2003-08-05 AU AU2003255390A patent/AU2003255390B2/en not_active Ceased
- 2003-08-05 WO PCT/EP2003/008749 patent/WO2004014953A2/en not_active Ceased
2004
- 2004-11-30 IL IL165478A patent/IL165478A/en not_active IP Right Cessation
- 2004-11-30 IS IS7576A patent/IS7576A/en unknown
- 2004-12-03 NO NO20045323A patent/NO333876B1/en not_active IP Right Cessation
2008
- 2008-04-01 US US12/060,555 patent/US8071731B2/en not_active Expired - Fee Related
2014
- 2014-01-14 CY CY20141100027T patent/CY1114919T1/en unknown

Also Published As

Publication number	Publication date
US8071731B2 (en)	2011-12-06
JP4528121B2 (en)	2010-08-18
MXPA05001468A (en)	2005-06-06
EP1526868A2 (en)	2005-05-04
IS7576A (en)	2004-11-30
ES2440652T3 (en)	2014-01-29
NO20045323L (en)	2005-02-10
HK1077206A1 (en)	2006-02-10
CA2494008A1 (en)	2004-02-19
AR040778A1 (en)	2005-04-20
JP2006512899A (en)	2006-04-20
US20060165681A1 (en)	2006-07-27
DK1526868T3 (en)	2014-01-13
AU2003255390A1 (en)	2004-02-25
CN100542607C (en)	2009-09-23
PL211014B1 (en)	2012-03-30
PL375405A1 (en)	2005-11-28
US7612183B2 (en)	2009-11-03
NZ537123A (en)	2007-05-31
SI1526868T1 (en)	2014-01-31
AU2003255390B2 (en)	2011-02-03
NO333876B1 (en)	2013-10-07
TWI323265B (en)	2010-04-11
CA2494008C (en)	2012-12-11
MY148409A (en)	2013-04-30
WO2004014953A2 (en)	2004-02-19
TW200403254A (en)	2004-03-01
KR20050049470A (en)	2005-05-25
EP1526868B1 (en)	2013-10-23
CN1671417A (en)	2005-09-21
CY1114919T1 (en)	2016-12-14
KR101078459B1 (en)	2011-10-31
PT1526868E (en)	2014-01-07
US20090053214A1 (en)	2009-02-26
BR0312456A (en)	2005-04-19
WO2004014953A3 (en)	2004-05-06

Publication	Publication Date	Title
IL165478A (en)	2010-12-30	Humanized anti-myelin associated glycoprotein (mag) antibody and pharmaceutical composition comprising such antibody
IL164021A (en)	2013-04-30	Anti-alphavbeta6 antibodies and pharmaceutical compositions containing the same
IL211385A0 (en)	2011-04-28	Anti-cd33 antibodies or epitope-binding fragments thereof and pharmaceutical compositions containing the same
EP1551447A4 (en)	2007-03-07	Anti-addl antibodies and uses thereof
EP1572131A4 (en)	2009-07-29	Antibody therapy
IL158643A (en)	2010-12-30	Anti-hmg monoclonal antibodies and compositions containing the same
EP1539129A4 (en)	2006-03-08	Dosage forms and related therapies
AU2002365649A8 (en)	2003-06-17	Anti-dota antibody
HUP0303163A3 (en)	2008-03-28	Tramadol-based pharmaceutical composition
AU2003299581A8 (en)	2004-06-23	Antibodies against drugs of abuse
GB0117057D0 (en)	2001-09-05	Pharmaceutical composition
EG24516A (en)	2009-08-19	Peptide deformylase inhibitors
GB0129117D0 (en)	2002-01-23	Pharmaceutical composition
EP1408896A4 (en)	2010-02-24	Pharmaceutical composition
IL166063A0 (en)	2006-01-15	Antibodies and uses thereof
GB0116107D0 (en)	2001-08-22	Pharmaceutical composition
AU2003210054A1 (en)	2003-10-08	Anti-rank monoclonal antibodies and pharmaceutical composition containing the same
PL370037A1 (en)	2005-05-16	Pharmaceutical composition
EP1383729A4 (en)	2006-04-19	Peptide deformylase inhibitors
EP1456647A4 (en)	2006-10-18	Methods for identifying and validating potential drug targets---
AU2002255634A1 (en)	2002-09-19	Peptide deformylase inhibitors
IL157411A0 (en)	2004-03-28	Pharmaceutical composition
AU2003212418A8 (en)	2003-09-02	Peptide deformylase
AU2003270518A8 (en)	2004-04-30	Therapeutic anti-bgp(c-cam1) antibodies and uses thereof
AU2002238318A1 (en)	2002-09-19	Abca5 transporter and uses thereof

Legal Events

Date	Code	Title
2011-04-28	FF	Patent granted
2013-08-29	KB	Patent renewed
2018-02-28	MM9K	Patent not in force due to non-payment of renewal fees